-
1.发明申请Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment 失效心肌梗塞，中风和PAOD的易感基因; 治疗方法公开(公告)号：US20070280917A1
公开(公告)日：2007-12-06
申请号：US11270804
申请日：2005-11-09
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.
摘要翻译： FLAP和LTA4H基因的多态性通过遗传关联分析显示为心肌梗死（MI）和ACS以及中风和PAOD的敏感性标志物。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。 本发明还提供了通过向受试者施用包含治疗有效量的体内抑制白细胞三烯合成的MI治疗剂的组合物的组合，在具有包括黑非洲血统的种族的人类受试者中预防MI治疗的方法。 本发明还提供了包含白三烯合成抑制剂和他汀类的组合物以及使用这些组合物降低患有MI，ACS，中风和/或PAOD风险的人类受试者中的C-反应蛋白的方法。
-
公开(公告)号：US20050272051A1
公开(公告)日：2005-12-08
申请号：US10944272
申请日：2004-09-17
IPC分类号： A61K31/00 , A61K31/198 , A61K31/381 , A61K31/445 , A61P9/10 , C12Q1/68 , G01N33/50
CPC分类号： A61K31/00 , A61K31/198 , A61K31/381 , A61K31/445 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： Linkage of myocardial infarction (MI) with a locus on chromosome 12q23 is disclosed. In particular, the LTA4H gene within this locus is shown by association analysis to be a susceptibility gene for MI. Methods for preventing and/or treating the recurrence of MI, in particular are described.
摘要翻译： 公开了心肌梗塞（MI）与染色体12q23上的位点的连锁。 特别地，通过关联分析将该基因内的LTA4H基因显示为MI的易感基因。 特别是描述了用于预防和/或治疗MI复发的方法。
-
3.发明申请Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment 审中-公开心肌梗塞，中风和PAOD的易感基因，治疗方法公开(公告)号：US20060019269A1
公开(公告)日：2006-01-26
申请号：US11096191
申请日：2005-03-30
IPC分类号： C12Q1/68 , A61K31/401 , A61K31/366 , A61K31/225
CPC分类号： A61K31/225 , A61K31/366 , A61K31/401 , A61K38/00 , C07K14/4705 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N2800/324
摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a stating and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.
摘要翻译： 公开了心肌梗塞（MI）和染色体13q12上的位点的连锁。 特别地，通过遗传关联分析将该基因内的FLAP基因显示为MI和ACS以及中风和PAOD的易感基因。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。 本发明还提供包含白三烯合成抑制剂的组合物和使用这些组合物降低患有MI，ACS，中风和/或PAOD风险的人类受试者的C-反应蛋白的说明和方法。
-
4.发明申请Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment 失效心肌梗塞，中风和PAOD的易感基因; 治疗方法公开(公告)号：US20050113408A1
公开(公告)日：2005-05-26
申请号：US10830477
申请日：2004-04-22
CPC分类号： C12Q1/6883 , A61K38/00 , C07K14/4705 , C12Q2600/156 , G01N2800/324
摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.
摘要翻译： 公开了心肌梗塞（MI）和染色体13q12上的位点的连锁。 特别地，通过遗传关联分析将该基因内的FLAP基因显示为MI和ACS以及中风和PAOD的易感基因。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。
-
公开(公告)号：US20050282855A1
公开(公告)日：2005-12-22
申请号：US10769744
申请日：2004-01-30
CPC分类号： A61K31/47 , A61K38/00 , C07K14/4705 , C12Q1/6883 , C12Q2600/156 , G01N2800/324
摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.
-
6.发明申请Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment 审中-公开心肌梗死，脑卒中，Paod及其治疗方法的易感基因公开(公告)号：US20080293750A1
公开(公告)日：2008-11-27
申请号：US10587412
申请日：2005-01-31
IPC分类号： A61K31/505 , C12Q1/02 , A61K31/40 , A61P9/10 , C12Q1/68
CPC分类号： C07K14/4705 , A61K38/00 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N2800/324
摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a stating and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.
摘要翻译： 公开了心肌梗塞（MI）和染色体13q12上的位点的连锁。 特别地，通过遗传关联分析将该基因内的FLAP基因显示为MI和ACS以及中风和PAOD的易感基因。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。 本发明还提供包含白三烯合成抑制剂的组合物和使用这些组合物降低患有MI，ACS，中风和/或PAOD风险的人类受试者的C-反应蛋白的说明和方法。
-
7.发明授权Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment 失效心肌梗塞，中风和PAOD的易感基因; 治疗方法公开(公告)号：US07851486B2
公开(公告)日：2010-12-14
申请号：US10830477
申请日：2004-04-22
IPC分类号： A61K31/47
CPC分类号： C12Q1/6883 , A61K38/00 , C07K14/4705 , C12Q2600/156 , G01N2800/324
摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.
摘要翻译： 公开了心肌梗塞（MI）和染色体13q12上的位点的连锁。 特别地，通过遗传关联分析将该基因内的FLAP基因显示为MI和ACS以及中风和PAOD的易感基因。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。
-
8.发明申请GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION 审中-公开有用于冠状动脉疾病和心肌梗塞风险评估的遗传变异公开(公告)号：US20100120045A1
公开(公告)日：2010-05-13
申请号：US12598180
申请日：2008-04-30
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/172
摘要： The invention relates to methods of risk assessment and diagnosis of susceptibility to coronary artery disease and myocardial infarction, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with coronary artery disease and myocardial infarction. The invention also relates to methods for use of such polymorphic markers for predicting drug response to drugs for treating cardiovascular disease, or for monitoring the effectiveness of such drugs. The invention further relates to kits encompassing reagents for use in these methods.
摘要翻译： 本发明涉及通过评估发现与冠状动脉疾病和心肌梗死相关的某些多态性标志物的等位基因的存在或不存在而对冠状动脉疾病和心肌梗死的易感性进行风险评估和诊断的方法。 本发明还涉及使用这种多态性标记物预测用于治疗心血管疾病的药物的药物应答或用于监测这些药物的有效性的方法。 本发明还涉及包含用于这些方法的试剂的试剂盒。
-
公开(公告)号：US09617597B2
公开(公告)日：2017-04-11
申请号：US12302538
申请日：2008-02-21
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/172 , Y02A90/26
摘要： The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease. MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers.
-
公开(公告)号：US20090325163A1
公开(公告)日：2009-12-31
申请号：US12302463
申请日：2007-12-05
CPC分类号： C12Q1/6827 , C12Q1/6837 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G06F19/18
摘要： The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.
摘要翻译： 本发明涉及通过评估发现与心房颤动，心房颤动和中风相关的多态性标记处的等位基因的存在或不存在来确定心律失常易感性的方法和方法，包括心房颤动，心房扑动和中风。 本发明还涉及包含用于评估这种标记的试剂的试剂盒，以及用于利用这种敏感性标记物的诊断方法，用途和程序。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.043 秒)
